Screener
Rapport Therapeutics, Inc. RAPP Shares (Diluted)
Shares (Diluted) at other companies
Other financials
Where this comes from
Reported directly by Rapport Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding.
The source filing: Rapport Therapeutics, Inc.’s 10-Q, filed August 5, 2026.
- Filed
- Aug 5, 2026, 7:30 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001193125-26-333862
| Line item | For the Three Months Ended June 30, 2026 | For the Three Months Ended June 30, 2025 | For The Six Months Ended June 30, 2026 | For The Six Months Ended June 30, 2025 |
|---|---|---|---|---|
| Total other income | 4,191 | 2,764 | 8,549 | 5,809 |
| Net loss | $(56,615) | $(26,732) | $(76,472) | $(50,795) |
| Net loss per share attributable to common stockholders, basic and diluted | $(1.19) | $(0.75) | $(1.61) | $(1.44) |
| Weighted-average common shares outstanding, basic and diluted | 47,473,174 | 35,444,635 | 47,355,550 | 35,356,098 |
| Comprehensive loss: | ||||
| Net loss | $(56,615) | $(26,732) | $(76,472) | $(50,795) |
| Change in unrealized (losses) gains on investments, net of tax | (765) | 19 | (1,816) | 446 |
| Total other comprehensive income (loss) | (765) | 19 | (1,816) | 446 |
Item 1. Financial Statements.
FAQ
- What is Rapport Therapeutics, Inc.'s shares (diluted)?
- Rapport Therapeutics, Inc. (RAPP) reported shares (diluted) of 47.5M in Q2 2026.
- How has Rapport Therapeutics, Inc.'s shares (diluted) changed year-over-year?
- Rapport Therapeutics, Inc.'s shares (diluted) increased by 33.9% year-over-year, from 35.4M to 47.5M.
- What does shares (diluted) mean?
- The weighted-average shares outstanding plus all potentially dilutive shares from stock options, RSUs, convertible securities, and warrants, using the treasury stock method.
Ask your AI about Rapport Therapeutics, Inc.'s shares (diluted).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude